801 related articles for article (PubMed ID: 27913931)
1. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
Liu S; Foulkes WD; Leung S; Gao D; Lau S; Kos Z; Nielsen TO
Breast Cancer Res; 2014 Sep; 16(5):432. PubMed ID: 25193543
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
4. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.
Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY
PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825
[TBL] [Abstract][Full Text] [Related]
5. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
6. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
8. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma.
Ryu HS; Park YS; Park HJ; Chung YR; Yom CK; Ahn SH; Park YJ; Park SH; Park SY
Thyroid; 2014 Aug; 24(8):1232-40. PubMed ID: 24742251
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
Stanton SE; Disis ML
J Immunother Cancer; 2016; 4():59. PubMed ID: 27777769
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer.
Ma X; Zhao X; Yan W; Yang J; Zhao X; Zhang H; Hui Y; Zhang S
Cancer Biomark; 2018 Feb; 21(3):639-650. PubMed ID: 29286921
[TBL] [Abstract][Full Text] [Related]
12. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer.
Chen Y; Klingen TA; Aas H; Wik E; Akslen LA
J Pathol Clin Res; 2021 Sep; 7(5):517-527. PubMed ID: 34076969
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy.
Chen TH; Zhang YC; Tan YT; An X; Xue C; Deng YF; Yang W; Yuan X; Shi YX
Oncotarget; 2017 Jan; 8(3):5219-5232. PubMed ID: 28029650
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.
Ogiya R; Niikura N; Kumaki N; Bianchini G; Kitano S; Iwamoto T; Hayashi N; Yokoyama K; Oshitanai R; Terao M; Morioka T; Tsuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Cancer Sci; 2016 Dec; 107(12):1730-1735. PubMed ID: 27727484
[TBL] [Abstract][Full Text] [Related]
17. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer.
Shen Z; Zhou S; Wang Y; Li RL; Zhong C; Liang C; Sun Y
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1585-95. PubMed ID: 20221835
[TBL] [Abstract][Full Text] [Related]
18. The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma.
Wang J; Tian S; Sun J; Zhang J; Lin L; Hu C
BMC Cancer; 2020 Aug; 20(1):731. PubMed ID: 32758195
[TBL] [Abstract][Full Text] [Related]
19. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
20. Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes.
Fukui R; Fujimoto Y; Watanabe T; Inoue N; Bun A; Higuchi T; Imamura M; Morimoto K; Hirota S; Miyoshi Y
Anticancer Res; 2020 Apr; 40(4):2141-2150. PubMed ID: 32234907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]